| Contract Development and Manufacturing Services (CDMO) | End-to-end drug development, late-stage clinical APIs, high-potency API manufacturing, technology transfer, ADC & bioconjugation services. | Strong chemistry expertise, extensive global GMP facilities, regulatory approvals, integrated R&D to commercial scale capabilities, and strategic geographic spread. | Pharmaceutical innovators, biotech companies globally seeking specialized drug substance and product manufacturing. | High-potency APIs, ADC manufacturing, late phase clinical development, and aseptic injectable fills. | 1649 | 61 | Revenue from contract research, development services, commercial API manufacture, and licensing agreements with pharma customers (B2B). | Predominantly project-based contracts with milestone payments, long-term supply agreements, and fee-for-service. | Increasing demand for oncology APIs, ADC expansions, regulatory approvals, clinical pipeline growth, and integration of Swiss-India facilities. | Carbogen Amcis, Dishman HiPo facility |
| Marketable Molecules (Vitamin-D, Bulk Drugs, Quats, Specialty Chemicals) | Manufacture and sale of vitamin D analogues, cholesterol, specialty chemicals, disinfectants, and related bulk drugs. | Long-standing manufacturing expertise, established supplier and customer networks, regulatory certifications, and product quality consistency. | Pharmaceutical companies, healthcare product manufacturers, and industrial customers globally. | Vitamin D analogues and cholesterol segment provides stable cash flows with moderate margins. | 491 | 18 | Revenue from sales of manufactured chemical and pharmaceutical products to pharma and industrial clients (B2B). | Direct sales with negotiated contracts for volumes based on market demand and supply agreements. | Rising demand for vitamin D analogues, growth in cholesterol derivatives, cost optimization initiatives, and customer acquisition in new geographies. | Vitamin D analogues, Cholesterol precursors, Quaternary ammonium compounds |
